2023
Master transcription factor reprograming unleashes selective translation promoting castration resistance and immune evasion in lethal prostate cancer.
Santasusagna S, Zhu S, Jawalagatti V, Carceles-Cordon M, Ertel A, Garcia-Longarte S, Song W, Fujiwara N, Li P, Mendizabal I, Petrylak D, Kelly W, Reddy E, Wang L, Schiewer M, Lujambio A, Karnes J, Knudsen K, Cordon-Cardo C, Dong H, Huang H, Carracedo A, Hoshida Y, Rodriguez-Bravo V, Domingo-Domenech J. Master transcription factor reprograming unleashes selective translation promoting castration resistance and immune evasion in lethal prostate cancer. Cancer Discovery 2023, 13: 2584-2609. PMID: 37676710, PMCID: PMC10714140, DOI: 10.1158/2159-8290.cd-23-0306.Peer-Reviewed Original ResearchConceptsLethal prostate cancerProstate cancerCastration resistanceImmune evasionPharmacologic targetingAnti-PD-1 therapyMajor histocompatibility complex IDeprivation therapyMicrophthalmia transcription factorAndrogen receptorPreclinical modelsTherapeutic strategiesCancerTherapyDruggable mechanismMaster transcription factorTranscription factorsKey mRNAsSpecific mRNAsMRNAFactor 3bEvasionSelected ArticlesTargetingTumors
2008
404 POSTER A phase I study of oral administration of the histone deacetylase (HDAC) inhibitor belinostat in patients (pts) with advanced solid tumors
Kelly W, Petrylak D, Blumenschein G, Lassen U, Jensen P, DeBono J. 404 POSTER A phase I study of oral administration of the histone deacetylase (HDAC) inhibitor belinostat in patients (pts) with advanced solid tumors. European Journal Of Cancer Supplements 2008, 6: 127. DOI: 10.1016/s1359-6349(08)72338-3.Peer-Reviewed Original Research
2006
139 POSTER Phase I dose escalation safety/tolerance study of PPl-2458 in subjects with Non-Hodgkin's lymphoma or solid tumors
Stiede K, Eder J, Anthony S, Conkling P, Fayad L, Petrylak D, Sausville E, Verschraegen C, Bhat G. 139 POSTER Phase I dose escalation safety/tolerance study of PPl-2458 in subjects with Non-Hodgkin's lymphoma or solid tumors. European Journal Of Cancer Supplements 2006, 4: 45. DOI: 10.1016/s1359-6349(06)70145-8.Peer-Reviewed Original Research
2001
Cure of undifferentiated small cell carcinoma of the urinary bladder with M-VAC chemotherapy
Nejat R, Purohit R, Goluboff E, Petrylak D, Rubin M, Benson M. Cure of undifferentiated small cell carcinoma of the urinary bladder with M-VAC chemotherapy. Urologic Oncology Seminars And Original Investigations 2001, 6: 53-55. PMID: 11166621, DOI: 10.1016/s1078-1439(00)00098-3.Peer-Reviewed Original ResearchSmall cell carcinomaUrinary bladderCell carcinomaUndifferentiated small cell carcinomaM-VAC chemotherapyRecurrence 3 yearsRadical surgeryPathologic evidenceRadical cystoprostatectomyCisplatin chemotherapyAggressive malignancyApparent cureChemotherapyBladderCarcinomaCureCystectomyCystoprostatectomyPatientsSurgeryMalignancyRadiotherapyTumorsAdriamycin